Differences in aqueous humor protein profiles in patients with proliferative diabetic retinopathy before and after conbercept treatment

被引:2
|
作者
Wang, Tan [1 ,2 ]
Chen, Huan [1 ,2 ]
Du, Xiaolan [1 ,2 ]
Li, Ningning [3 ]
Chen, Youxin [1 ,2 ]
Min, Hanyi [1 ,2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Ophthalmol, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Key Lab Ocular Fundus Dis, Beijing 100730, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Operating Room, Beijing 100730, Peoples R China
关键词
Proliferative diabetic retinopathy; Proteomics; Conbercept; LC-MS; MS; INTRAVITREAL CONBERCEPT; DATA INTEGRATION; R PACKAGE; FEATURES;
D O I
10.1016/j.jprot.2023.104838
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
To investigate the changes in aqueous humor (AH) protein profiles before and after intravitreal conbercept (IVC) treatment in proliferative diabetic retinopathy (PDR) patients. Ten PDR patients provided 20 samples of AH before (pre group) and after (post group) IVC treatment. Liquid chromatography-tandem mass spectrometry was performed to identify proteins. Bioinformatics analysis was used to explore the functional relevance of differ-entially expressed proteins (DEPs) and hub proteins. Parallel reaction monitoring (PRM) method was used to verify the hub proteins in another 8 samples of AH before and after IVC treatment in 4 PDR patients. A total of 30 DEPs were identified, consisting of 14 downregulated proteins and 16 upregulated proteins. Bioinformatics analysis indicated that DEPs mostly involved in neutrophil degranulation, antioxidant activity, secretory granule lumen, cytoplasmic vesicle lumen, vesicle lumen, and fluid shear stress. HP, VEGFA, CTSD, and LYZ were identified as hub proteins, among which HP and CTSD were verified by PRM. In addition to decreasing the intravitreal vascular endothelial growth factor level, IVC may alter the AH protein profile in PDR patients, especially HP and CTSD, with the DEPs involved in neutrophil degranulation, antioxidant activity, secretory granule lumen, cytoplasmic vesicle lumen, vesicle lumen, and fluid shear stress. Significance: Patients with proliferative diabetic retinopathy (PDR) regularly receive intravitreal conbercept treatment these days. The effect of this treatment has been determined by previous studies. However, the mechanism of IVC in PDR is not eventually determined. No studies have compared the aqueous humor (AH) protein profile before and after IVC treatment in the same patient. This is a topic deserving of further exploration. A proteomic method based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) was utilized in this study to analyze and assess the AH samples to explore the mechanism underlying the effects of IVC treatment on PDR.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Differences in aqueous humor protein profiles in patients with proliferative diabetic retinopathy before and after aflibercept treatment
    Wang, Tan
    Chen, Huan
    Du, Xiaolan
    Qiu, M. M. Bintao
    Li, Ningning
    Min, Hanyi
    BMC OPHTHALMOLOGY, 2024, 24 (01)
  • [2] Differences in Vitreous Protein Profiles in Patients With Proliferative Diabetic Retinopathy Before and After Ranibizumab Treatment
    She, Xinping
    Zou, Chen
    Zheng, Zhi
    FRONTIERS IN MEDICINE, 2022, 9
  • [3] Comparison of aqueous humor levels of PlGF and VEGF in proliferative diabetic retinopathy before and after intravitreal conbercept injection
    Zhang, Xiao
    Wu, Jie
    Wu, Chan
    Bian, Ai-ling
    Geng, Shuang
    Dai, Rong-ping
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 162
  • [4] Effect of intravitreal conbercept treatment before vitrectomy in proliferative diabetic retinopathy
    Mao, Jian-Bo
    Wu, Han-Fei
    Chen, Yi-Qi
    Zhao, Shi-Xin
    Tao, Ji-Wei
    Zhang, Yun
    Zheng, Bin
    Wang, Lin
    Shen, Li-Jun
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2018, 11 (07) : 1217 - 1221
  • [5] Effect of intravitreal conbercept treatment before vitrectomy in proliferative diabetic retinopathy
    Jian-Bo Mao
    Han-Fei Wu
    Yi-Qi Chen
    Shi-Xin Zhao
    Ji-Wei Tao
    Yun Zhang
    Bin Zheng
    Lin Wang
    Li-Jun Shen
    International Journal of Ophthalmology, 2018, (07) : 1217 - 1221
  • [6] Difference in the Vitreal Protein Profiles of Patients with Proliferative Diabetic Retinopathy with and without Intravitreal Conbercept Injection
    Zou, Chen
    Zhao, Minjie
    Yu, Jingjing
    Zhu, Dandan
    Wang, Yunzhi
    She, Xinping
    Hu, Yanan
    Zheng, Zhi
    JOURNAL OF OPHTHALMOLOGY, 2018, 2018
  • [7] Eicosanoid Profiles in the Vitreous Humor of Patients with Proliferative Diabetic Retinopathy
    Lin, Albert L.
    Roman, Richard J.
    Regan, Kathleen A.
    Bolch, Charlotte A.
    Chen, Ching-Jygh
    Iyer, Siva S. R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (20) : 1 - 13
  • [8] Effect of intravitreal conbercept injection on VEGF-A and -B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy
    Zhang, Yunda
    Gao, Zhao
    Zhang, Ximei
    Yuan, Zhigang
    Ma, Tao
    Li, Gaiyun
    Gao, Xiaohong
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (04)
  • [9] Aqueous Humor and Plasma Adiponectin Levels in Proliferative Diabetic Retinopathy Patients
    Mao, Danna
    Peng, Hui
    Li, Qiuhong
    Wang, Jun
    Li, Pinghua
    Hu, Ke
    Zhang, Xuedong
    Lei, Bo
    CURRENT EYE RESEARCH, 2012, 37 (09) : 803 - 808
  • [10] Safety and efficacy of intravitreal conbercept injection after vitrectomy for the treatment of proliferative diabetic retinopathy
    Ren, Xinjun
    Bu, Shaochong
    Zhang, Xiaomin
    Jiang, Yuanfeng
    Tan, Liangzhang
    Zhang, Hong
    Li, Xiaorong
    EYE, 2019, 33 (07) : 1177 - 1183